Vaccine Trial to Prevent Dengue Fever Developed at National Institute for Health

A large-scale clinical trial to evaluate whether a candidate vaccine can prevent the mosquito-borne illness dengue fever has been launched in Brazil. The vaccine, TV003, was developed by scientists in the laboratory of Stephen Whitehead, Ph.D., at NIH’s National Institute of Allergy and Infectious Diseases (NIAID). The Butantan Institute, a non-profit producer of immunobiologic products for Brazil, licensed the NIAID dengue vaccine technology and is sponsoring the placebo-controlled, multi-center Phase 3 trial using test vaccine produced in Sao Paulo.

Click for more information

Click for more information

Dengue fever is common in many parts of the tropics and subtropics and about half the world’s population is at risk of infection. The World Health Organization estimates that up to 400 million dengue infections occur annually, resulting in 500,000 hospitalizations. More than 1.5 million cases of dengue were reported in Brazil in 2015.

Dengue is caused by any of four related viruses, termed serotypes DEN-1, DEN-2, DEN-3 and DEN-4, which are transmitted to people by Aedes aegypti mosquitoes. A person exposed to one dengue virus type gains immunity to that type, but not to the other three. In fact, a second infection with a virus type that differs from the first can lead to a more severe course of disease.

“Researchers in NIAID’s Laboratory of Infectious Diseases spent many years developing and testing dengue vaccine candidates designed to elicit antibodies against all four dengue virus serotypes,” said NIAID Director Anthony S. Fauci, M.D. “Earlier clinical trials of this candidate conducted in the United States by NIAID showed that it could elicit a robust antibody and cellular immune response after just one dose,” he added. “Because the impact of dengue fever in Brazil is especially large and the country has an excellent health infrastructure, it is an ideal location to test the vaccine candidate.”

The new trial aims to enroll almost 17,000 healthy people aged 2 to 59 years in 13 cities, beginning in Sao Paulo. Two-thirds of the volunteers will receive a single dose of the candidate vaccine, while one-third will receive an inactive placebo injection. Neither participants nor study staff will know which of the two groups a volunteer is in. All volunteers will be monitored for five years through a combination of in-person visits to the health clinic and telephone or text communications from the investigators. The goal of the trial is determine if the candidate vaccine prevents dengue fever and to provide additional information about its safety. Although the trial is scheduled to last five years, the investigators hope to have early indications of the potential efficacy of the vaccine in less than two years. The principal investigator is Alexander Precioso, M.D., Ph.D., of the Butantan Institute.

Additional information about the trial is available at http://clinicaltrials.gov (link is external) using the identifier NCT02406729 (link is external).

Learn more about dengue fever and NIAID’s research projects to treat and prevent it and about the development of TV003 vaccine.

NIAID conducts and supports research — at NIH, throughout the United States, and worldwide — to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

Komohana Street Reconstruction Work Begins Tuesday

Starting Tuesday, January 19, 2016, the Komohana Street Reconstruction work will proceed with a ONE LANE, ONE-WAY 24-hour traffic pattern in the Waiānuenue Avenue direction (Hāmākua bound) between the Kūkūau Street intersection and the Ponahawai Street Intersection to accommodate pavement reconstruction work.  The contractor, Yamada and Sons, Inc. plans to expedite the work and complete this phase of the project by Friday, February 19, 2016, weather and construction conditions permitting.

The following lane changes will be in effect during this period.

  1. Puna bound on Komohana Street from Waiānuenue Avenue, left turn only at Ponahawai intersection.
  2. Entering Komohana Street from Ponahawai Street, no left turn onto Komohana Street.
  3. Entering Komohana Street from Huali Place, no left turn onto Komohana Street.

komohana project

As work progresses, the opening of the southbound lane from Huali Place will be implemented.

The following lanes will remain open:

  1. Kūkūau intersection open to travel in all directions.
  2. On Komohana Street, Hāmākua bound, right turn onto Huali Place.
  3. On Komohana Street, Hāmākua bound, right turn and straight through at the Ponahawai intersection.

Motorists are advised to expect delays and to drive with caution as heavy vehicles and machinery will be in the work zone.

Hawai‘i County Department of Public Works apologizes for any inconvenience this may cause and thanks the community for their patience and understanding.

If there are any questions or concerns, please call Yamada and Sons, Inc. at (808) 933-8434 or Barett Otani, County of Hawai‘i Department of Public Works Information and Education Specialist, at (808) 961-8787.

Updated Map Shows New Risk Areas for Potential Dengue Infection on the Big Island of Hawaii

An updated map of potential areas of infection by mosquito for confirmed dengue fever cases has been released:

Dengue Risk 11416This map should not be used to exclude any areas of the island from proactive mosquito control measures. All residents islandwide are encouraged to Fight The Bite by reducing mosquito breeding grounds and protecting themselves from mosquito bites.

Confirmed Dengue Fever Cases on the Big Island of Hawaii Rises to 218

The Dengue Fever outbreak on the Big Island continues and the total confirmed amount of cases rose by 3 more case since the last update bringing the total amount of confirmed cases to 218.

Mosquito Bite

As of January 14, 2016*:

Since the last update, HDOH has identified 3 new cases of dengue fever.  Currently, as many as 2 of the confirmed cases to date are potentially infectious to mosquitoes. All others are no longer infectious.

Potentially infectious individuals
2 Illness onset  1/6/16 – 1/8/16
Cases no longer infectious
216 Illness onset 9/11/15 to 1/3/16
Past and present confirmed cases (Cumulative TOTAL)
218

Of the confirmed cases, 197 are Hawaii Island residents and 21 are visitors.
177 cases have been adults; 41 have been children (<18 years of age). Onset of illness has ranged between 9/11/15 – 1/8/16.

As of today, a total of 893 reported potential cases have been excluded based on test results and/or not meeting case criteria.